190 related articles for article (PubMed ID: 29032266)
21. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
23. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Yegin ZA; Özkurt ZN; Dikyar A; Kaynar LA; Karacaoğlu Ö; Yağcı M
Transplant Proc; 2021; 53(6):2013-2020. PubMed ID: 34246474
[TBL] [Abstract][Full Text] [Related]
25. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.
Elsawy M; Storer BE; Milano F; Sandmaier BM; Delaney C; Salit RB; Rashad AH; Woolfrey AE; Appelbaum FR; Storb R; Sorror ML
Biol Blood Marrow Transplant; 2019 May; 25(5):1045-1052. PubMed ID: 30500442
[TBL] [Abstract][Full Text] [Related]
27. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
28. Pretransplant serum FT3 levels in recipients predict early non-relapse mortality after myeloablative allogeneic haematopoietic cell transplantation from matched sibling donors.
Li H; Chen J; Shi B; Chen X; Wu D; Wang Y
Hematology; 2018 Jan; 23(1):38-43. PubMed ID: 28651453
[TBL] [Abstract][Full Text] [Related]
29. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
30. Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.
Michelis FV; Messner HA; Uhm J; Alam N; Lambie A; McGillis L; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):e73-81. PubMed ID: 25458081
[TBL] [Abstract][Full Text] [Related]
31. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts.
McDonald GB; Sandmaier BM; Mielcarek M; Sorror M; Pergam SA; Cheng GS; Hingorani S; Boeckh M; Flowers MD; Lee SJ; Appelbaum FR; Storb R; Martin PJ; Deeg HJ; Schoch G; Gooley TA
Ann Intern Med; 2020 Feb; 172(4):229-239. PubMed ID: 31958813
[TBL] [Abstract][Full Text] [Related]
32. Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
Ando T; Fujisawa S; Teshigawara H; Matsumura A; Sakuma T; Suzuki T; Teranaka H; Ogusa E; Ishii Y; Miyashita K; Takahashi H; Nakajima Y; Miyazaki T; Hagihara M; Matsumoto K; Yamazaki E; Nakajima H
Int J Hematol; 2020 Jul; 112(1):46-56. PubMed ID: 32451786
[TBL] [Abstract][Full Text] [Related]
33. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.
Logan AC; Wang Z; Alimoghaddam K; Wong RM; Lai T; Negrin RS; Grumet C; Logan BR; Zhang MJ; Spellman SR; Lee SJ; Miklos DB;
Biol Blood Marrow Transplant; 2015 Apr; 21(4):746-54. PubMed ID: 25572032
[TBL] [Abstract][Full Text] [Related]
34. A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage-Related Complications in Allogeneic Transplantation.
Tatekawa S; Kohno A; Ozeki K; Watamoto K; Ueda N; Yamaguchi Y; Kobayashi T; Yokota I; Teramukai S; Taniwaki M; Kuroda J; Morishita Y
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1573-1581. PubMed ID: 27246373
[TBL] [Abstract][Full Text] [Related]
35. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
[TBL] [Abstract][Full Text] [Related]
36. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.
Rondón G; Saliba RM; Chen J; Ledesma C; Alousi AM; Oran B; Hosing CM; Kebriaei P; Khouri IF; Shpall EJ; Popat UR; Champlin RE; Ciurea SO
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2166-2171. PubMed ID: 28844946
[TBL] [Abstract][Full Text] [Related]
37. Low serum albumin levels prior to pediatric allogeneic HCT are associated with increased need for critical care interventions and increased 6-month mortality.
Teagarden AM; Skiles JL; Beardsley AL; Hobson MJ; Moser EAS; Renbarger JL; Rowan CM
Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28670844
[TBL] [Abstract][Full Text] [Related]
38. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
39. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
[TBL] [Abstract][Full Text] [Related]
40. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
Guilfoyle R; Demers A; Bredeson C; Richardson E; Rubinger M; Szwajcer D; Seftel MD
Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
